Boston Scientific (BSX) projected strong growth. They said their heart-device technology was gaining share in the market. Investors were told the momentum would keep accelerating. But behind the scenes, new competition was beginning to put pressure on the business.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
A federal lawsuit filed in Massachusetts alleges that Boston Scientific and several of its top executives misled investors about the growth trajectory of its electrophysiology business, contributing to a sharp single-day stock decline following the disclosure of disappointing earnings and guidance in early 2026.
According to a complaint filed on March 5, 2026, in the United States District Court for the District of Massachusetts, investors who purchased Boston Scientific common stock between July 23, 2025, and February 3, 2026, may have suffered losses when the stock fell approximately 17.6% in a single day following the company’s fourth quarter 2025 earnings release. The case is captioned Troike v. Boston Scientific Corporation et al., Case No. 4:26-cv-40075.
If you purchased Boston Scientific stock during the class period and experienced losses, you may wish to learn more about your potential legal options.
Who Is Boston Scientific
Boston Scientific Corporation is a Massachusetts-based global medical device company headquartered in Marlborough, Massachusetts, with its common stock traded on the New York Stock Exchange under the ticker symbol BSX. Among its many product lines, the company operates an Electrophysiology segment that develops and manufactures devices used in the detection and treatment of heart rate and rhythm disorders. Its flagship product in this segment is the Farapulse Pulsed Field Ablation system.
The company’s EP business became a central driver of investor attention and revenue projections during 2025, as management repeatedly highlighted its growth potential and competitive positioning in public statements and earnings calls.
What the Lawsuit Claims
The lawsuit alleges that Boston Scientific and its senior executives repeatedly made positive statements about the sustainability of EP segment growth while allegedly concealing material adverse trends, including competitive pressures, slowing procedure volumes, and regulatory and reimbursement headwinds. The complaint alleges that management knew or recklessly disregarded that growth in the U.S. EP franchise was approaching a tipping point earlier than the market was led to believe.
The result, according to the complaint, was that investors purchased Boston Scientific shares at artificially inflated prices and were then surprised when the company disclosed underwhelming guidance and a net income miss in early 2026.
If you want to stay informed as this case develops, consider following updates related to the lawsuit.
What Management Said
According to the complaint, CEO Michael Mahoney stated in July 2025 that the company delivered “another excellent quarter” and that management was raising full-year 2025 guidance to forecast organic net sales growth of 14 to 15%. At the company’s September 30, 2025, Analyst and Investor Day, EVP and Group President of Cardiology Joseph Fitzgerald described EP as the largest and fastest-growing market in medical technology, projecting the market would grow at 15% over the long-range plan.
Nicholas Spadea-Anello, Global President of Electrophysiology, stated at the same event that the company saw “strong adoption of PFA” and expected PFA penetration to grow from 50% globally to 80% by 2028, expressing confidence in the company’s ability to lead the market. In December 2025, Fitzgerald addressed competitive concerns by saying management had “a very good understanding of what competition we will face and in what time frame,” characterizing increased competition as standard for the industry. At a JPMorgan conference in January 2026, Mahoney described Boston Scientific as “blessed” to have WATCHMAN and FARAPULSE and continued to characterize the concomitant procedure as a significant tailwind exclusive to Boston Scientific.
When the Alleged Truth Emerged
On February 4, 2026, before markets opened, Boston Scientific released its fourth-quarter and full-year 2025 results, along with 2026 guidance that fell well below analyst expectations. The company reported that Q4 GAAP earnings per share of $0.45 fell below its own guided range of $0.48 to $0.52, and issued full-year 2026 organic revenue growth guidance of 10.0 to 11.0%, below analyst consensus of approximately 11.4%.
The earnings release and call reflected weakness in U.S. EP performance. During the Q&A, analysts described U.S. EP as flat sequentially versus the third quarter, and management acknowledged that new competitive entrants had contributed to market share losses. Boston Scientific’s stock fell from a closing price of $91.62 on February 3, 2026, to $75.50 on February 4, 2026, a decline of approximately 17.6% in a single trading session. Following the disclosure, multiple research firms lowered their price targets, with one analyst noting that “the deceleration in BSX’s U.S. EP franchise was steeper than we expected” and came “earlier than we had modeled.”
Why This Matters to Shareholders
The complaint alleges that investors who bought Boston Scientific shares during the class period did so in reliance on statements that painted an overly optimistic picture of the EP segment’s growth, durability, and competitive positioning. The lawsuit contends that management was aware of competitive risks and market saturation dynamics but continued to issue upwardly revised guidance while publicly downplaying those risks.
When the alleged truth emerged through the February 4, 2026, earnings release, the significant stock price decline suggests the market had not previously priced in the degree of deceleration management now acknowledged. Shareholders who purchased during the class period and held shares through the corrective disclosure may have sustained losses directly tied to the alleged misrepresentations.
The Legal Claims
The complaint asserts claims under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated by the SEC, alleging that defendants made materially false and misleading statements and omitted material facts in connection with the purchase and sale of Boston Scientific securities. A second claim under Section 20(a) of the Exchange Act is brought against the individual defendants, alleging they exercised control over the company and are therefore liable for the underlying violations.
The plaintiff alleges that defendants knew, or were recklessly indifferent to, the fact that statements about EP growth were materially misleading given the competitive and market dynamics they were aware of at the time.
If you are a Boston Scientific shareholder who purchased during the period from July 23, 2025, to February 3, 2026, you may want to explore your rights with qualified legal counsel.
About Levi & Korsinsky, LLP
Levi & Korsinsky, LLP is a nationally recognized securities litigation firm representing investors in complex shareholder actions. The firm has extensive expertise and a team of over 70 employees to serve our clients. Attorney advertising. Prior results do not guarantee similar outcomes.
Disclaimer: This article is provided for informational purposes only and does not constitute legal advice. No attorney-client relationship is created by reading this article. Past results do not guarantee similar outcomes.